布列维单疗或组合治疗慢性肝炎 达尔塔:2025年更新
Pietro Lampertico1,2,3, Maria Paola Anolli1,2,3, Katja Steppich3,4,5,6
1Division of Gastroenterology and Hepatology, Foundation IRCCS ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Journal of viral hepatitis
|November 25, 2025
概括
慢性肝炎Delta (CHD) 具有攻击性,但布莱维 (BLV) 提供了新的希望. 这次审查考察了BLV的BLV.
科学领域:
- 肝病学和病毒学,专注于病毒性肝炎和肝脏疾病.
- 药理学和治疗学,特别是抗病毒药物开发.
- 公共卫生和流行病学,解决病毒感染的全球流行.
背景情况:
- 慢性肝炎Delta (CHD) 是病毒性肝炎最具侵略性的形式,其特征是肝硬化加速,肝功能衰退和肝细胞癌 (HCC) 风险.
- 型肝炎病毒 (HDV) 需要乙型肝炎病毒表面抗原 (HBsAg) 进入,但目前的核胺类比疗法对慢性心脏病无效.
- 在HBsAg+患者中,全球HDV患病率估计为2% (极星天文台,2024年),具有显著的区域差异,特别是蒙古的高率.
研究的目的:
- 审查布莱维 (BLV) 在治疗慢性型肝炎中的疗效,有效性和安全性.
- 综合从临床试验和BLV的现实世界研究中获得的证据,无论是作为单一疗法还是与基化干扰素-α (PegIFNα) 结合.
- 根据疾病严重程度和患者个人资料,根据不断变化的治疗环境,提出基于心血管疾病的治疗策略.
主要方法:
- 系统审查和综合目前关于布莱维尔 (BLV) 疗效和安全的证据.
- 从临床试验 (第二阶段和第三阶段) 和现实研究中分析数据.
- 评估BLV作为单一治疗和与基化干扰素-α (PegIFNα) 结合的作用.
主要成果:
- 布列维尔提德 (BLV) 是一种向NTCP受体的进入抑制剂,在治疗补偿性心脏病时已显示出有效性和耐受性.
- 欧洲药物管理局 (EMA) 在2020年批准了BLV的条件批准,并在2023年批准了BLV的全部批准.
- BLV在治疗冠状动脉疾病方面显示出潜力,在临床益处得到证明之前,对其使用进行持续推.
结论:
- 布列维尔提德 (BLV) 代表了慢性肝炎三角体 (CHD) 治疗的重大进展.
- 进一步的研究和现实世界的数据对于优化BLV治疗策略和了解长期结果至关重要.
- 该审查旨在通过为心血管疾病患者提供量身定制的治疗方法来指导临床实践.
相关概念视频
Retrovirus Life Cycles
49.2K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
49.2K
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
1.1K
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
1.1K
Diseases of the Liver and Gallbladder
1.8K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.8K
Venous Thrombosis III: Interprofessional Care
268
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
268
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
427
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
427
Subviral Agents
485
Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
485


